Hemostemix (CVE:HEM) Trading 27.8% Higher – What’s Next?

Hemostemix Inc. (CVE:HEM) shares were up 27.8% during trading on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 335,071 shares changed hands during trading, a decline of 31% from the average daily volume of 486,759 shares. The stock had previously closed at C$0.09.

Hemostemix Stock Up 27.8%

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$16.76 million, a P/E ratio of -3.35 and a beta of 0.20. The stock’s 50-day simple moving average is C$0.10 and its 200 day simple moving average is C$0.14.

Insider Transactions at Hemostemix

In related news, Director Peter Alan Lacey acquired 200,000 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were bought at an average price of C$0.15 per share, with a total value of C$30,000.00. Insiders own 10.43% of the company’s stock.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.